Robert Rissman, PhD

Professor of Physiology and Neuroscience and the W.M. Keck Endowed Professor in Medicine, Director Neuroscience Translational Research Division and Biomarker Laboratory and Biorepository Director, Alzheimer's Therapeutic Research Institute

Biography

Dr. Rissman is Professor Physiology and Neuroscience and the W.M. Keck Endowed Professor in Medicine.  He is the founding Director of the Neuroscience Translational Research Division and the ATRI Biomarker Laboratory and Biorepository. He is the Alzheimer’s Clinical Trials Consortium (ACTC) Biorepository Unit Lead.

The ATRI facility is comprised by a wet laboratory and a large biorepository of -80 freezers to store specimens from clinical trials and longitudinal cohort studies. Using single analyte and multiplex bioassays, the goal of the lab is to identify biomarkers for preclinical AD and better understand how treatment parameters may impact these biomarkers. Concurrently with work at ATRI, Dr. Rissman is a PI at the VA San Diego, Professor of Neurosciences at UC San Diego and leads the ADCS Biomarker Core and ADRC Neuropathology Core.

The goal of Dr. Rissman’s basic science research is on novel biomarker discovery in Alzheimer’s Disease (AD) and preclinical studies in experimental. A major focus of his lab in AD biomarkers is on the utility and mechanistic underpinnings of neuronal exosomes and his group has published manuscripts demonstrating the ability of tau and abeta in neuronal exosomes to predict conversion from MCI to AD. The lab also investigates the contribution of stress and changes in stress signaling intermediates in Alzheimer’s disease neuropathology. Using transgenic mice and in vivo pharmacology, experiments are focused on identifying the role of corticotropin-releasing factor (CRF) receptors in beta-amyloid deposition, tau phosphorylation and behavioral and synaptic changes.

Publications

Brain cell type-specific enhancer-promoter interactome maps and disease-risk association. Science. 2019 Nov 29;366(6469):1134-1139.

The innate immunity protein IFITM3 modulates γ-secretase in Alzheimer’s disease. Nature. 2020 Oct;586(7831):735-740.

Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report Brain. 2019 Jun 1;142(6):1503-1527.

Noncanonical transnitrosylation network contributes to synapse loss in Alzheimer’s disease Science. 2021 Jan 15;371(6526):eaaw0843.

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease J Neuroinflammation. 2017 Jan 3;14(1):1.

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.